I-Mab Subsidiary Visara Assigns VIS-101 License to Everest Medicines
I'm PortAI, I can summarize articles.
I-Mab's subsidiary Visara has assigned its exclusive license for VIS-101 to Everest Medicines. This agreement allows Everest Medicines to develop, manufacture, and commercialize VIS-101 in Greater China, Singapore, South Korea, and select Southeast Asian countries. The information was originally published by I-Mab via EDGAR on October 30, 2025.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments